New York State Common Retirement Fund Has $82,000 Stock Position in Accuray Incorporated (NASDAQ:ARAY)

New York State Common Retirement Fund lessened its stake in Accuray Incorporated (NASDAQ:ARAY) by 22.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,096 shares of the medical equipment provider’s stock after selling 8,393 shares during the quarter. New York State Common Retirement Fund’s holdings in Accuray were worth $82,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Commonwealth Equity Services LLC acquired a new stake in shares of Accuray in the third quarter valued at approximately $35,000. Kestra Advisory Services LLC bought a new position in Accuray in the third quarter valued at about $42,000. Mackenzie Financial Corp acquired a new stake in Accuray in the third quarter worth about $58,000. Williams & Novak LLC bought a new stake in Accuray during the 4th quarter worth about $76,000. Finally, Dynamic Advisor Solutions LLC lifted its position in Accuray by 39.8% during the 4th quarter. Dynamic Advisor Solutions LLC now owns 32,155 shares of the medical equipment provider’s stock valued at $89,000 after purchasing an additional 9,155 shares during the period. 64.08% of the stock is owned by institutional investors.

Accuray Price Performance

Shares of ARAY stock opened at $1.63 on Friday. The firm has a market capitalization of $161.77 million, a price-to-earnings ratio of -7.41 and a beta of 1.48. Accuray Incorporated has a 12-month low of $1.51 and a 12-month high of $4.30. The company has a quick ratio of 0.78, a current ratio of 1.58 and a debt-to-equity ratio of 4.05. The firm has a fifty day moving average of $2.21 and a 200-day moving average of $2.54.

Accuray (NASDAQ:ARAY) last announced its quarterly earnings results on Wednesday, May 1st. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.05). Accuray had a negative return on equity of 44.46% and a negative net margin of 4.99%. The business had revenue of $101.13 million during the quarter, compared to the consensus estimate of $114.60 million. During the same quarter last year, the company earned $0.01 earnings per share. On average, equities research analysts forecast that Accuray Incorporated will post -0.16 earnings per share for the current year.

Analyst Upgrades and Downgrades

ARAY has been the topic of several analyst reports. TheStreet lowered shares of Accuray from a “c-” rating to a “d+” rating in a report on Wednesday, February 14th. Roth Mkm began coverage on Accuray in a report on Tuesday, February 13th. They issued a “buy” rating and a $9.00 price objective for the company. Finally, Roth Capital restated a “buy” rating on shares of Accuray in a report on Tuesday, February 13th. One investment analyst has rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $8.25.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.